The British biotech company Vidac Pharma (ISIN GB00BM9XQ619) has reached an important milestone in the development of innovative cancer therapies. The US Patent Office has granted the Company a groundbreaking patent for a completely new therapeutic approach: the treatment aims to normalize the metabolism of cancer cells – an approach that experts refer to as "Warburg effect reversal".
News & Events